Drug intelligence / Profile preview

REGN3048

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

REGN3048 is a fully human neutralizing monoclonal antibody that targets the spike glycoprotein of Middle East respiratory syndrome coronavirus (MERS-CoV). It was developed by Regeneron Pharmaceuticals and is designed to be used in combination with another monoclonal antibody, REGN3051, to reduce virus replication in infected individuals. In preclinical studies, the combination of REGN3048 and REGN3051 showed enhanced efficacy in reducing viral titers, lung inflammation, and pathology compared to either antibody alone.

Targets

MERS-CoV S-RBD (MERS-CoV spike receptor-binding domain)

Beyond the preview

Go deeper on REGN3048.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN3048.

Explore the full profile